Kairos Pharma, LTD.

Kairos Pharma is a clinical-stage biopharmaceutical company developing a diversified portfolio of antibody and small-molecule drug candidates to address multiple cancers by targeting immune suppression and drug resistance. The company's pipeline includes candidates in development for prostate cancer, lung cancer, breast cancer, and glioblastoma, with therapies designed to deplete regulatory T cells, block checkpoint pathways, reverse tumor-associated immunosuppression, and restore chemotherapy sensitivity. Kairos operates with minimal overhead using partnerships with academic medical centers for clinical trial execution, while licensing intellectual property from Cedars-Sinai Medical Center and other institutions; the company generates no revenue until successful clinical development and regulatory approval, with future monetization dependent on licensing arrangements, partnerships, and eventual commercialization of approved candidates in large oncology markets.